Figure 2.
Progression-free survival of newly diagnosed chronic myeloid leukemia patients treated with 400 mg imatinib daily according to Sokal risk at diagnosis.
Progression-free survival of newly diagnosed chronic myeloid leukemia patients treated with 400 mg imatinib daily according to Sokal risk at diagnosis.
